|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2400092200 |
|
最近更新日期: Date of Last Refreshed on: |
2024-11-12 11:24:36 |
|
注册时间: Date of Registration: |
2024-11-12 00:00:00 |
|
注册号状态: |
补注册 |
|
Registration Status: |
Retrospective registration |
|
注册题目: |
基于EEG探讨头针孙氏情感区治疗卒中后认知障碍患者的临床疗效和中枢机制 |
|
Public title: |
Clinical Efficacy and Central Mechanisms of Scalp Acupuncture in the Sun’s Emotional Area for Treating Post-Stroke Cognitive Impairment: An EEG-Based Study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于EEG探讨头针孙氏情感区治疗卒中后认知障碍患者的临床疗效和中枢机制 |
|
Scientific title: |
Clinical Efficacy and Central Mechanisms of Scalp Acupuncture in the Sun’s Emotional Area for Treating Post-Stroke Cognitive Impairment: An EEG-Based Study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
李慎微 |
研究负责人: |
王东岩 |
|
Applicant: |
Shenwei Li |
Study leader: |
Dongyan Wang |
|
申请注册联系人电话: Applicant telephone: |
+86 176 7413 7488 |
研究负责人电话:
Study leader's |
+86 188 4617 8610 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wilsonlee@wmu.edu.cn |
研究负责人电子邮件: Study leader's E-mail: |
532257395@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
中国哈尔滨市南岗区果戈里大街411号 |
研究负责人通讯地址: |
中国哈尔滨市南岗区果戈里大街411号 |
|
Applicant address: |
411 Gogoli Street, Nangang District, Harbin City, Heilongjiang Province , China |
Study leader's address: |
411 Gogoli Street, Nangang District, Harbin City, Heilongjiang Province , China |
|
申请注册联系人邮政编码: Applicant postcode: |
1500000 |
研究负责人邮政编码: Study leader's postcode: |
150000 |
|
申请人所在单位: |
黑龙江中医药大学附属第二医院 |
||
|
Applicant's institution: |
The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine |
||
|
研究负责人所在单位: |
黑龙江中医药大学附属第二医院 |
||
|
Affiliation of the Leader: |
The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2023-K171 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
黑龙江中医药大学附属第二医院伦理委员会 |
||
|
Name of the ethic committee: |
The Ethics Committee of the Second Afiliated Hospital of Heilongjiang University of Chinese Medicine |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2023-03-30 00:00:00 | ||
|
伦理委员会联系人: |
王大伟 |
||
|
Contact Name of the ethic committee: |
Dawei Wang |
||
|
伦理委员会联系地址: |
中国哈尔滨市南岗区果戈里大街411号 |
||
|
Contact Address of the ethic committee: |
411 Gogoli Street, Nangang District, Harbin City, Heilongjiang Province , China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 451 5362 8834 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
黑龙江中医药大学附属第二医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
中国哈尔滨市南岗区果戈里大街411号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
411 Gogoli Street, Nangang District, Harbin City, Heilongjiang Province , China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
本研究得到了国家自然科学基金面上项目(82374601)、黑龙江省自然科学基金联合引导项目(LH2019H113)和黑龙江中医药大学创新团队建设项目(2017sit01)的资助。 |
||||||||||||||||||||||
|
Source(s) of funding: |
This study was supported by grants from the National Natural Science Foundation of China, No.82374601, and Natural Science Foundation of Heilongjiang Province, No.LH2019H113, and the Science Foundation of Heilongjiang University of Chinese Medicine, No.2017sit01. |
||||||||||||||||||||||
|
研究疾病: |
卒中后认知障碍 |
||||||||||||||||||||||
|
Target disease: |
Post stroke cognitive impairment |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
1.观察针刺孙氏情感区改善卒中后认知障碍(PSCI)的临床疗效,比较不同针刺方法对PSCI患者认知域影响的差异。 2.探究针刺孙氏情感区对PSCI患者大脑皮层中各个脑区神经电活动的调控作用,揭示针刺孙氏情感区的中枢效应机制。 3.明确PSCI患者大规模脑网络的时空动力学特性,为解释PSCI的发病机制提供证据,以及探究针刺孙氏情感区对PSCI患者脑网络动态活动模式的调节作用,为解析针刺孙氏情感区的中枢效应机制提供更为丰富的依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
1.To observe the clinical efficacy of acupuncture at the Sun-style emotional region in improving post-stroke cognitive impairment (PSCI) and to compare the differential effects of different acupuncture methods on cognitive domains in PSCI patients. 2.To investigate the regulatory effect of acupuncture at the Sun-style emotional region on the neural electrical activity in various brain regions of PSCI patients, elucidating the central mechanism of acupuncture at the Sun-style emotional region. 3.To clarify the spatiotemporal dynamic characteristics of large-scale brain networks in PSCI patients, providing evidence for explaining the pathogenesis of PSCI, as well as exploring the regulatory effect of acupuncture at the Sun-style emotional region on the dynamic activity patterns of brain networks in PSCI patients, thereby providing a richer basis for understanding the central mechanism of acupuncture at the Sun-style emotional region. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.符合2021版《卒中后认知障碍管理专家共识》中PSCI障碍的诊断标准; 2.右利手; 3.年龄在35~75周岁,性别不限,病程在6月之内; 4.意识清醒,病情稳定,能够配合完成试验; 5.无严重运动、言语、听力、视力障碍,及影响疗效评价的其他疾病; 6.无严重心、肺、肾功能损害; 7.7天内未服用精神类药物; 8.卒中前未患有认知功能障碍性疾病; 9.同意并签署知情同意书 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Meet the diagnostic criteria for PSCI disorder in the 2021 edition of the Expert Consensus on the Management of Cognitive Impairment after Stroke; 2. Right hand; 3. Age 35~75 years old, gender is not limited, the course of the disease is within 6 months; 4. Conscious, stable condition, able to cooperate with the completion of the test; 5. No serious motor, speech, hearing, visual impairment, and other diseases that affect the evaluation of efficacy; 6. No serious heart, lung and kidney damage; 7. No psychotropic medication within 7 days; 8. No cognitive dysfunction disease before stroke; 9. Agree and sign the informed consent form |
||||||||||||||||||||||
|
排除标准: |
1.卒中前被诊断为阿尔茨海默病、路易体痴呆等认知功能障碍疾病; 2.MoCA量表评分≥22分; 3.存在严重视力、听力、语言和运动障碍,生命体征不稳定,无法完成检查者; 4.伴有严重心、肺、肾、肝、造血和内分泌功能损害; 5.妊娠或哺乳期妇女; 6.具有严重精神疾病的患者,既往癫痫、抑郁症、精神分裂症等; 7.脑电监测前,患者正在服用或7天内使用过作用于中枢神经系统的药物,如镇静催眠、抗癫痫和抗精神病药; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Diagnosed with cognitive dysfunction diseases such as Alzheimer's disease and Lewy body dementia before stroke; 2. MoCA scale score≥ 22 points; 3. Those who have severe visual, hearing, speech and motor impairments, unstable vital signs, and are unable to complete the examination; 4. Accompanied by severe cardiac, lung, kidney, liver, hematopoietic and endocrine damage; 5. Pregnant or lactating women; 6. Patients with severe mental illness, previous epilepsy, depression, schizophrenia, etc.; 7. Before EEG monitoring, the patient is taking or has used drugs that act on the central nervous system, such as sedative-hypnotic, antiepileptic and antipsychotic drugs, within 7 days; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2023-03-30 00:00:00至 To 2024-03-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2023-04-01 00:00:00 至 To 2024-03-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
结束 /Completed |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究统计人员利用SPSS 26生成随机数字,并且通过软件内置随机方法将随机数字分组。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Researchers used SPSS 26 to generate random numbers and grouped them using the software's built-in randomization method. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
单盲;对研究参与者设盲 |
|
Blinding: |
Single-blind; Study participants were blinded |
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
研究结束后,通过邮箱与研究者联系 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After the study is over, contact the investigator by email |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |